Cantor Fitzgerald set a $10.00 price objective on Amarin (NASDAQ:AMRN) in a research report released on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. HC Wainwright reaffirmed a buy rating on shares of Amarin in a report on Thursday, March 1st. ValuEngine raised Amarin from a sell rating to a hold rating in a report on Wednesday, May 2nd. Zacks Investment Research raised Amarin from a sell rating to a hold rating in a report on Thursday, February 15th. Finally, BidaskClub downgraded Amarin from a buy rating to a hold rating in a report on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $7.75.

Shares of Amarin opened at $3.21 on Monday, MarketBeat Ratings reports. The company has a current ratio of 1.74, a quick ratio of 1.45 and a debt-to-equity ratio of -2.30. Amarin has a fifty-two week low of $3.16 and a fifty-two week high of $3.24.

Amarin (NASDAQ:AMRN) last announced its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $43.80 million for the quarter, compared to analysts’ expectations of $43.75 million. During the same period in the prior year, the company earned ($0.08) earnings per share. The company’s revenue for the quarter was up 26.6% on a year-over-year basis. analysts predict that Amarin will post -0.38 EPS for the current year.

In related news, General Counsel Joseph T. Kennedy sold 26,942 shares of the stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $2.90, for a total value of $78,131.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.08% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. OppenheimerFunds Inc. lifted its stake in Amarin by 20.9% in the 4th quarter. OppenheimerFunds Inc. now owns 7,897,310 shares of the biopharmaceutical company’s stock worth $31,668,000 after acquiring an additional 1,365,720 shares in the last quarter. Clearbridge LLC lifted its stake in Amarin by 9.8% in the 4th quarter. Clearbridge LLC now owns 4,867,366 shares of the biopharmaceutical company’s stock worth $19,518,000 after acquiring an additional 435,340 shares in the last quarter. Opaleye Management Inc. lifted its stake in Amarin by 102.9% in the 1st quarter. Opaleye Management Inc. now owns 1,745,000 shares of the biopharmaceutical company’s stock worth $5,252,000 after acquiring an additional 885,000 shares in the last quarter. Two Sigma Investments LP lifted its stake in Amarin by 41.1% in the 4th quarter. Two Sigma Investments LP now owns 1,547,977 shares of the biopharmaceutical company’s stock worth $6,207,000 after acquiring an additional 450,755 shares in the last quarter. Finally, Highland Capital Management LP lifted its stake in Amarin by 152.5% in the 4th quarter. Highland Capital Management LP now owns 1,197,000 shares of the biopharmaceutical company’s stock worth $4,800,000 after acquiring an additional 723,000 shares in the last quarter. 38.07% of the stock is owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.